Safety of conditioning agents for allogeneic haematopoietic transplantation

Bibliography

• Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
   PubMed Web of Science ®Google Scholar
• Laane E, Derolf AR, Bjorklund E, et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006;91:833-6
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007;39:71-87
   PubMed Web of Science ®Google Scholar
• Vicente D, Lamparelli T, Gualandi F, et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant 2007;40:349-54
   PubMed Web of Science ®Google Scholar
• Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14:8-15
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63
   PubMed Web of Science ®Google Scholar
• Storb R. Non-myeloablative allogeneic transplantation – state-of-the-art. Pediatr Transplant 2004;8(Suppl 5):12-8
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005;9:151-5
   Google Scholar
• Styler MJ, Crilley P, Biggs J, et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant 1996;18:171-6
   PubMed Web of Science ®Google Scholar
• Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005;90:1396-404
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005;128:690-7
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Giebel S, Wojnar J, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008. In press
   Google Scholar
• Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008;14:1936-49
   PubMed Web of Science ®Google Scholar
• Zander AR, Dicke KA, Keating M, et al. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer 1985;56:1374-9
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Yau JC, Huan SD, et al. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. Am J Hematol 1994;46:82-6
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-9
   PubMed Web of Science ®Google Scholar
• Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007;20:85-90
   PubMed Web of Science ®Google Scholar
• Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant 2008;41:415-23
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006;38:203-9
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100:1201-7
   PubMed Web of Science ®Google Scholar
• Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70:1382-8
   PubMed Web of Science ®Google Scholar
• Santos GW. Marrow transplantation in acute nonlymphocytic leukemia. Blood 1989;74:901-8
   PubMed Web of Science ®Google Scholar
• Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood 1994;84:2144-50
   PubMed Web of Science ®Google Scholar
• Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994;14:759-65
   PubMed Web of Science ®Google Scholar
• Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-30
   PubMed Web of Science ®Google Scholar
• Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42
   PubMed Web of Science ®Google Scholar
• Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008;28:1502-10
   PubMed Web of Science ®Google Scholar
• Bruno B, Souillet G, Bertrand Y, et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004;34:143-7
   PubMed Web of Science ®Google Scholar
• Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002;8:145-54
   PubMed Web of Science ®Google Scholar
• Madden T, de LM, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13:56-64
   PubMed Web of Science ®Google Scholar
• Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-85
   PubMed Web of Science ®Google Scholar
• Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:307-14
   PubMed Web of Science ®Google Scholar
• Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35:17-23
   PubMed Web of Science ®Google Scholar
• Shimoni A, Bielorai B, Toren A, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol 2003;31:428-34
   PubMed Web of Science ®Google Scholar
• Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001;114:944-50
   PubMed Web of Science ®Google Scholar
• Cho YH, Lim HA, Lee MH, et al. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clin Transplant 2007;21:417-22
   PubMed Web of Science ®Google Scholar
• Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998;22:439-43
   PubMed Web of Science ®Google Scholar
• Kanda Y, Sakamaki H, Sao H, et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant 2005;11:881-9
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Ploemacher RE, Boudewijn A, et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000;60:5470-8
   PubMed Web of Science ®Google Scholar
• Sjoo F, Hassan Z, bedi-Valugerdi M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 2006;34:115-21
   PubMed Web of Science ®Google Scholar
• Lee HJ, Gulbis A, De Padua SL, et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 2008;42:67-9
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008;143:548-51
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Blau IW, Trenschel R, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007;39:389-96
   PubMed Web of Science ®Google Scholar
• Sauer M, Zeidler C, Meissner B, et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone Marrow Transplant 2007;39:143-7
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Mohren M, Jentsch-Ullrich K, et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004;34:477-83
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005;35:233-41
   PubMed Web of Science ®Google Scholar
• Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004;33:259-69
   PubMed Web of Science ®Google Scholar
• Seber A, Shu XO, Defor T, et al. Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 1999;23:35-40
   PubMed Web of Science ®Google Scholar
• Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995;29:918-21
   PubMed Web of Science ®Google Scholar
• Andersson BS, Gajewski J, Donato M, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000;25(Suppl 2):S35-8
   PubMed Web of Science ®Google Scholar
• Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992;79:2578-82
   PubMed Web of Science ®Google Scholar
• Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002;119:1115-24
   PubMed Web of Science ®Google Scholar
• Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994;83:2723-30
   PubMed Web of Science ®Google Scholar
• Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99
   PubMed Web of Science ®Google Scholar
• Cornford EM, Young D, Paxton JW, et al. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 1992;52:138-43
   PubMed Web of Science ®Google Scholar
• Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;26:1107-9
   PubMed Web of Science ®Google Scholar
• Marks R, Potthoff K, Hahn J, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008;112:415-25
   PubMed Web of Science ®Google Scholar
• Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7
   PubMed Web of Science ®Google Scholar
• Hunter HM, Peggs K, Powles R, et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning–evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005;128:496-502
   PubMed Web of Science ®Google Scholar
• Petropoulos D, Worth LL, Mullen CA, et al. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplant 2006;37:463-7
   PubMed Web of Science ®Google Scholar
• Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002;30:367-73
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 2007;21:2109-16
   PubMed Web of Science ®Google Scholar
• Hutton JJ, Von Hoff DD, Kuhn J, et al. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984;44:4183-6
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6
   PubMed Web of Science ®Google Scholar
• Juranic Z, Radic J, Konic-Ristic A, et al. Antibodies contained in “M” component of some patients with multiple myeloma are directed to food antigens? Leuk Res 2006;30:1585-6
   PubMed Web of Science ®Google Scholar
• Leitman SF, Tisdale JF, Bolan CD, et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003;43:1667-71
   PubMed Web of Science ®Google Scholar
• Hutchinson K, Kopko PM, Muto KN, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion 2002;42:1567-72
   PubMed Web of Science ®Google Scholar
• Maung ZT, Wood AC, Jackson GH, et al. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994;88:649-52
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675-87
   PubMed Web of Science ®Google Scholar
• Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008;22:474-86
   PubMed Web of Science ®Google Scholar
• Willmore E, Frank AJ, Padget K, et al. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 1998;54:78-85
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995;6:325-41
   PubMed Web of Science ®Google Scholar
• Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7
   PubMed Web of Science ®Google Scholar
• Gassas A, Sung L, Saunders EF, Doyle JJ. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant 2006;38:739-43
   PubMed Web of Science ®Google Scholar
• Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008;42:175-80
   PubMed Web of Science ®Google Scholar
• Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant 2008;42:433-7
   PubMed Web of Science ®Google Scholar
• Wolff SN, Herzig RH, Fay JW, et al. High-dose N,N´, N´-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990;17:2-6
   PubMed Web of Science ®Google Scholar
• Teicher BA, Holden SA, Cucchi CA, et al. Combination of N,N´, N´-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 1988;48:94-100
   PubMed Web of Science ®Google Scholar
• Cohen NA, Egorin MJ, Snyder SW, et al. Interaction of N,N´, N´-triethylenethiophosphoramide and N,N´,N´-triethylenephosphoramide with cellular DNA. Cancer Res 1991;51:4360-6
   PubMed Web of Science ®Google Scholar
• van BK, Devine S, Wickrema A, et al. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant 2003;32:9-13
   PubMed Web of Science ®Google Scholar
• Devetten MP, Qazilbash MH, Beall CL, et al. Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplant 2004;34:577-80
   PubMed Web of Science ®Google Scholar
• Shen YC, Chiu CF, Chow KC, et al. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant 2004;34:609-14
   PubMed Web of Science ®Google Scholar
• Rossi HA, Becker PS, Emmons RV, et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;31:441-6
   PubMed Web of Science ®Google Scholar
• Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 1992;35:397-401
   PubMed Web of Science ®Google Scholar
• Waud WR, Schmid SM, Montgomery JA, Secrist JA, III. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000;19:447-60
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-23
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86
   PubMed Web of Science ®Google Scholar
• Lang et al. ASH annual meeting abstracts. Blood 2007;110:3019
   Google Scholar
• Agura et al. ASH annual meeting abstracts. Blood 2007;110:4954
   Google Scholar
• Martin MG, Uy GL, Procknow E, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009 [Epub ahead of print]
   Google Scholar
• Hows J, Bradley BA, Gore S, et al. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993;12:371-80
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-7
   PubMed Web of Science ®Google Scholar
• Ayuk F, Diyachenko G, Zabelina T, et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008;36:1047-54
   PubMed Web of Science ®Google Scholar
• Pihusch R, Holler E, Muhlbayer D, et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:347-54
   PubMed Web of Science ®Google Scholar
• Weber M, Kroger N, Langer F, et al. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:817-22
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De MM, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91
   PubMed Web of Science ®Google Scholar
• Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-12
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137-43
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121-7
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-8
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-25
   PubMed Web of Science ®Google Scholar
• Cull GM, Haynes AP, Byrne JL, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000;108:754-60
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7
   PubMed Web of Science ®Google Scholar
• Schlegel PG, Eyrich M, Bader P, et al. OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol 2000;111:668-73
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004;83:201-5
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Whartenby KA. Hematopoietic stem cell transplant as a platform for tumor immunotherapy. Curr Opin Mol Ther 2004;6:48-53
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Avigdor A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;122:457-64
   PubMed Web of Science ®Google Scholar
• Buser A, Stern M, Arber C, et al. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab? Bone Marrow Transplant 2008;42:483-7
   PubMed Web of Science ®Google Scholar
• Kellogg MD, Law T, Sakamoto M, Rifai N. Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit 2005;27:625-9
   PubMed Web of Science ®Google Scholar
• Koyama RG, Castro RM, De Mello MT, et al. Simple detection of large InDeLS by DHPLC: the ACE gene as a model. J Biomed Biotechnol 2008;2008:562183
   PubMedGoogle Scholar
• Duerst RE, Horan JT, Liesveld JL, et al. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 2000;25:489-94
   PubMed Web of Science ®Google Scholar
• Hänel M, Kroger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002;81:96-102
   PubMed Web of Science ®Google Scholar
• Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997;19:1169-73
   PubMed Web of Science ®Google Scholar
• Horstmann M, Stockschlader M, Kabisch H, Zander A. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors. Blood 1995;85:1404-5
   PubMed Web of Science ®Google Scholar
• Hessling J, Kroger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;119:769-72
   PubMed Web of Science ®Google Scholar
• Zander AR, Spitzer G. Autologous transplantation. In: Blume K, Petz L, editors, Clinical bone marrow transplantation. Churchill Livingstone; New York, Edinburgh, London, Melbourn, 1983;331-353
   Google Scholar